Despite their relatively small size, the nef genes of HIV-1, HIV-2, and SIV pack a big punch. Nef is a highly complex and multifunctional protein that intersects multiple host cellular pathways essential for cell survival and function. Despite extensive in vitro characterization, the role of Nef during in vivo infection remains unclear. In this issue of Cell, Schindler et al. (2006) present intriguing evidence suggesting that, during evolution, the Nef protein of HIV-1 lost its ability to downregulate host T cell receptor/ CD3 (TCR-CD3). This new characteristic of Nef may have provided HIV-1 with a dramatic pathogenic potential in its human host.
The Nef protein of HIV was originally viewed as a negative regulator of the long terminal repeat transcriptional promoter of HIV. As nef is one of the HIV-1 genes not required for viral production, it was named for its presumed negative role (negative factor). This notion was dismissed with the finding that Nef from the SIVmac strain was essential for the maintenance of high virus load and disease progression in rhesus macaques (Kestler et al., 1991) . Subsequently, similar observations were made with respect to HIV-1 Nef in a cohort of Australian patients infected after transfusions of blood containing a Nef-defective virus (Deacon et al., 1995) . These and other studies emphasize the importance of Nef in both HIV and SIV pathogenesis, and since then, multiple possible explanations for this dramatic in vivo phenotype have been proposed (Simmons et al., 2001) . Thus, Nef has been labeled a pathogenic factor.
In general, Nefs from all primate lentiviruses (HIV-1, HIV-2, and SIV) share multiple activities in vitro. These include downregulation of CD4, MHC class I proteins, and CD28 in host cells; enhanced infectivity of the viral particle; and activation of cellular kinases (Arora et al., 2002) . In their new work, Schindler et al. (2006) focus their attention on the one in vitro activity that is absent from all HIV-1 Nefs tested, namely the ability to induce host-cell TCR-CD3 downregulation. It is well established that HIV-1 Nef does not induce TCR-CD3 downregulation, whereas HIV-2 and most SIV Nefs do. The Schindler et al.
(2006) study now makes an important distinction regarding Nefs from different species. Specifically, the Nef protein of SIVcpz, the primate lentivirus that is most closely related to HIV-1, also does not induce host cells to downregulate TCR-CD3, whereas Nefs from SIVsmm, the closest primate virus to HIV-2 retain this ability.
Although sooty mangabeys are the natural host of SIVsmm, this strain of virus does not cause disease in a majority of these animals (Rey-Cuille et al., 1998), but it does in rhesus macaques (Schindler et al., 2006) . However, a small percentage of infected mangabeys do experience a decline in the number of their CD4 + T cells that correlates with increased activation of the immune system. Nefs from the viruses present in mangabeys that experienced CD4 + T cell loss were slightly defective in their ability to downregulate TCR-CD3. This result suggested that Nef may play an important protective role by maintaining low levels of immune activation in naturally infected primates. Therefore, the results from Schindler et al. (2006) In this issue of Cell, Schindler et al. (2006) show that the Nef protein from nonpathogenic strains of simian immunodeficiency virus (SIV) induces the downregulation of host T cell receptor/CD3, whereas Nef from human immunodeficiency virus (HIV-1) does not. This loss of function in the Nef of HIV-1 may partly explain the pathogenicity of this virus. (Schindler et al., 2006) . First, such downregulation blocks T cell activation in vitro by phytohemagglutinin (PHA) or antibodies against CD3/CD28. Second, this downregulation results in a marked decrease in activation-induced T cell death. Interestingly, there was no difference in the in vitro susceptibility of T cells to FAS-mediated apoptosis regardless of which Nef protein was expressed in peripheral blood mononuclear cells. Analysis of a truncated form of Nef that retains the ability to induce TCR-CD3 downregulation but is defective in other Nef activities demonstrated that TCR-CD3 downregulation is sufficient to inhibit T cell activation and activation-induced cell death.
However, Schindler et al. (2006) note several apparent exceptions to this view. For example, Nefs from SIVcpz (a chimpanzee virus that is the precursor to all HIV-1 strains) failed to induce TCR-CD3 downregulation, yet infection of chimpanzees with SIVcpz does not result in disease despite active viral replication. Another example is provided by humans infected with HIV-2. Schindler et al. (2006) show that HIV-2 is a powerful inducer of TCR-CD3 downregulation (2-fold higher than SIVsmm). Yet humans infected with HIV-2 develop AIDS, although at a slower rate (Marlink et al., 1994) . In addition, rhesus macaques infected with SIVsmm containing Nefs that are fully capable of inducing TCR-CD3 downregulation develop AIDS-like disease. Another interesting pathogenesis model is provided by infection of pigtailed macaques with the SIVagm strain, which induces AIDS-like disease (Goldstein et al., 2005) . SIVagmwhich downregulates TCR-CD3 (Schindler et al., 2006) -is not generally pathogenic in rhesus macaques (Muller and Barre-Sinoussi, 2003) . The authors suggest that the pathogenesis of SIVsmm in rhesus macaques may reflect host-species differences rather than a particular characteristic of this viral strain. More experimentation will be needed to reconcile the outcomes of infections with these different simian virus strains. Schindler et al. (2006) make another important point: If TCR-CD3 downregulation serves to maintain virus replication and persistence, how do primate species infected with SIV strains that have lost this ability manage their infections? Interestingly, all of these SIV strains have an additional gene, vpu. By dividing 30 Nef alleles into "group 1" or "group 2" based on the absence or presence, respectively, of the ability to induce TCR-CD3 downregulation, Schindler et al. (2006) found an excellent correlation between viruses carrying Nefs that do not induce downregulation of TCR-CD3 and the presence of the vpu gene. These viruses are HIV-1 strains from all three HIV-1 zoonoses (M, N, and O); SIVcpz from Pan t. troglodytes (the central African chimpanzee, which is the source of all three human zoonoses); SIVcpz from Pan t. schweinfurthii (the eastern chimpanzee, with no known transmissions to humans); and three simian viruses, SIVgsn, SIVmus, and SIVmon. Group 2 (the vpu-negative viruses whose Nefs induce TCR-CD3 downregulation) includes nine different simian viruses and HIV-2. The function of vpu in the management of viral infection awaits further investigation.
Phylogenetic analysis of the 30 Nefs suggests that the ability to induce downregulation of TCR-CD3 by host T cells was present in the viral progenitor of all group 1 and 2 viruses. Interestingly, this analysis demonstrated that group 1 and group 2 Nefs are not present in viruses from separate clades. This may reflect a recombination event between vpu-positive and vpu-negative viruses that generated a virus containing a vpu gene and a Nef capable of downregulating TCR-CD3. Subsequently, the nef newly associated with vpu presumably lost its capacity to induce TCR-CD3 downregulation. Based on their phylogenetic analysis, the authors conclude that the ability to induce TCR-CD3 downregulation has been lost twice during the evolution of primate lentiviruses. For example, the SIVrcm strain (which lacks vpu and downregulates TCR-CD3) is closely related to SIVcpz (the nonpathogenic precursor to HIV-1) with respect to the nef, gag, and pol genes, but the env gene of SIVcpz is not derived from SIVrcm. The fact that SIVcpz is nonpathogenic in chimpanzees and lacks TCR-CD3 downregulation abilities indicates the possibility that the pathogenesis of HIV-1 actually might not be related to the fact that its Nef cannot induce TCR-CD3 downregulation in host T cells.
The next step may be to engineer a highly infectious HIV-1 strain containing a Nef that downregulates TCR-CD3. By maintaining viral persistence in the context of an intact host immune system, this nonpathogenic virus could potentially outcompete pathogenic viruses. If such a result is observed, this finding may open the door to a fresh approach to developing a potentially safe and effective curative vaccine.
